Promoter holding
64.27%
DP
D.D. Pharmaceuticals Pvt. Ltd - Due diligence report
A 360° intelligence report on D.D. Pharmaceuticals Pvt. Ltd: trust score, financial health, credit view, compliance, directors, growth and d…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
D.D. Pharmaceuticals Pvt. Ltd — 360° Intelligence Report
Generated from MCA filings & public records93/100
Trust Score
Low Risk
D.D. Pharmaceuticals Pvt. Ltd is assessed as Low Risk with a Trust Score of 93/100. D.D. Pharmaceuticals Pvt. Ltd is an active private limited indian non-government company incorporated in 1994, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.
Report generated on 10 Aug 2026 from the latest processed filings. D.D. Pharmaceuticals Pvt. Ltd snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreLow Risk
93/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
93/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
95/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
55/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
95/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
80/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 55/100 Moderate
- Liabilities ≈ 38% EBITDA - stretched.
- Open charges exceed net worth - secured lenders rank ahead.
- Moderate gearing (D/E 1.42).
- Working-capital cover adequate.
- Profitable - internal accruals available.
Charges position: 4 open (24.64 cr) · 8 satisfied (30.52 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Others | 7 | 48.0 cr |
| Bank Of Baroda | 3 | 48.0 cr |
| Icici Bank Limited | 1 | 48.0 cr |
| Rajasthan Financial Corporation | 1 | 48.0 cr |
Compliance Score: 93/100 Low Risk
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
- Litigation present in 1 court forum(s).
- 1 active GST registration(s).
Legal cases on record (1)
05
Director Intelligence
Stability score: 95/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| LALITA CHOUDHARY | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| AMIT KUMAR CHOUDHARY | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ALKA CHOUDHARY | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 3 directors on the board.
- No disqualified or deactivated DINs.
- Stable board - no exits in 3 years.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2023 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
1 allotment(s) · 0 transfer(s)
Promoters hold a dominant controlling stake - exact percentages are part of the full report.
Key managerial personnel: LALITA CHOUDHARY (Whole-time director) · AMIT KUMAR CHOUDHARY (Whole-time director) · ALKA CHOUDHARY (Whole-time director)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 95 · Distress 80
Growth signals & trust indicators
Revenue acceleration: +2.1x over 4 year(s).
Latest year revenue grew 24%.
Profit expanded 0.86 year-on-year.
Asset base grew 61% - capacity expansion.
EPFO headcount growing - hiring signal.
Operating for 31+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Outside liabilities up 38% in a year.
4 open charge(s) registered - assets are encumbered.
1 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence89/100
Favourable indicators
Suitability as a supplier / customer counterparty.
- Statutory record is clean.
- 1 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment76/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 4 open charge(s) of 24.64 cr already registered.
- Compliance record supports lending.
Investor view94/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 5 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events30 Sep 2025
Last AGM held
Annual general meeting
18 Jun 2025
Charge satisfied
Others
13 Jun 2025
Charge satisfied
Others
31 Mar 2025
Latest balance sheet
Filed with ROC
30 Jul 2024
Charge created
Others - 5.56 cr
22 May 2024
Charge created
Others - 3.50 cr
13 Mar 2024
Charge satisfied
Others
03 Sep 2022
Charge created
Others - 12.90 cr
04 Feb 2022
Charge created
Others - 44.80 Lakh
15 Dec 2021
Charge created
Others - 65.00 Lakh
27 Jul 2021
Charge created
Others - 67.50 Lakh
16 Jul 2021
Charge satisfied
Icici Bank Limited
27 Sep 2016
Charge satisfied
Bank Of Baroda
27 Jun 2016
Charge created
Others - 14.90 cr
29 Feb 2016
Charge created
Icici Bank Limited - 2.50 cr
10
Key Observations
Auto-generated from the data aboveRevenue grew 1.42 over the last 4 financial year(s).
Net profit margin moved from 2.1x to 24%.
Debt-to-equity stands at 0.86 - manageable leverage.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
3 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 1 security allotment(s) - amounts available in the full report.
| Company | CIN | Location |
|---|---|---|
| R. B. Agencies Private Limited | U74991UP2006PTC032620 | Kanpur, Uttar Pradesh, India |
| Revat Laboratories Private Limited | U24230TG1988PTC008741 | Hyderabad, Telangana, India |
| Paras Intermediates Private Limited | U24100MH1999PTC195984 | Mumbai, Maharashtra, India |
| Adroit Pharmachem Private Limited | U24100GJ2013PTC073351 | Vadodara, Gujarat, India |
| Krishna Conchem Products Private Limited | U24224MH1990PTC058387 | Thane, Maharashtra, India |
| Pellets Pharma | U24239TG2004PLC042853 | Hyderabad, Telangana, India |
| T. C. Health Care Private Limited | U74899UP1985PTC037371 | Modinagar, Uttar Pradesh, India |
| Kedia Guar Gum Private Limited | U01110RJ2012PTC039251 | Sadulpur, Rajasthan, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify D.D. Pharmaceuticals Pvt. Ltd before audits and certifications: compliance score 93/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of D.D. Pharmaceuticals Pvt. Ltd: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Favourable lending indicators. Credit risk score 55/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 95/100, margin trends, ownership structure and peer set for D.D. Pharmaceuticals Pvt. Ltd - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Favourable indicators. Trust score 93/100, distress signals and MSME payment-delay disclosures - know whether D.D. Pharmaceuticals Pvt. Ltd pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (1 case(s) on record), regulatory flags, charge documents trail and director networks for D.D. Pharmaceuticals Pvt. Ltd - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is D.D. Pharmaceuticals Pvt. Ltd an active company?
D.D. Pharmaceuticals Pvt. Ltd has MCA status “Active” with a compliance score of 93/100 (Low Risk).
Is D.D. Pharmaceuticals Pvt. Ltd financially healthy?
D.D. Pharmaceuticals Pvt. Ltd has a Financial Health Score of 95/100 (Low Risk) based on its filed financial statements.
Should I do business with D.D. Pharmaceuticals Pvt. Ltd?
Its overall Trust Score is 93/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls D.D. Pharmaceuticals Pvt. Ltd?
Promoters hold a dominant controlling stake - exact percentages are in the full report. 3 active director(s) are on record.
Does D.D. Pharmaceuticals Pvt. Ltd have loans or charges against its assets?
4 open charge(s) are registered against its assets, and 8 earlier charge(s) stand satisfied.
Is D.D. Pharmaceuticals Pvt. Ltd up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 93/100 (Low Risk).
Is it risky to lend to D.D. Pharmaceuticals Pvt. Ltd?
Its Credit Risk Score is 55/100 (Moderate). Banker verdict: Favourable lending indicators.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
